Erik Mannaert

1.6k total citations
49 papers, 1.2k citations indexed

About

Erik Mannaert is a scholar working on Psychiatry and Mental health, Molecular Biology and Pharmacology. According to data from OpenAlex, Erik Mannaert has authored 49 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Psychiatry and Mental health, 8 papers in Molecular Biology and 7 papers in Pharmacology. Recurrent topics in Erik Mannaert's work include Schizophrenia research and treatment (15 papers), Chronic Lymphocytic Leukemia Research (6 papers) and Bipolar Disorder and Treatment (6 papers). Erik Mannaert is often cited by papers focused on Schizophrenia research and treatment (15 papers), Chronic Lymphocytic Leukemia Research (6 papers) and Bipolar Disorder and Treatment (6 papers). Erik Mannaert collaborates with scholars based in Belgium, United States and Germany. Erik Mannaert's co-authors include Bart Remmerie, Mariëlle Eerdekens, Juthamas Sukbuntherng, Jan de Jong, Ilse Van Hove, Jan Snoeys, Paul Daenens, Peter Hellemans, Donna Skee and Loeckie De Zwart and has published in prestigious journals such as Gastroenterology, American Journal of Psychiatry and Cancer Research.

In The Last Decade

Erik Mannaert

48 papers receiving 1.2k citations

Peers

Countries citing papers authored by Erik Mannaert

Since Specialization

Citations

This map shows the geographic impact of Erik Mannaert's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Erik Mannaert with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Erik Mannaert more than expected).

Fields of papers citing papers by Erik Mannaert

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Erik Mannaert. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Erik Mannaert. The network helps show where Erik Mannaert may publish in the future.

Co-authorship network of co-authors of Erik Mannaert

This figure shows the co-authorship network connecting the top 25 collaborators of Erik Mannaert. A scholar is included among the top collaborators of Erik Mannaert based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Erik Mannaert. Erik Mannaert is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Single-dose pharmacokinetics of ibrutinib in subjects with varying degrees of hepatic impairment^* 2016 ·Leukemia & lymphoma ·Jan de Jong, Donna Skee, Peter Hellemans, James Jiao, Ronald de Vries, (unknown), Eric Lawitz, Thomas Marbury, William Smith, Juthamas Sukbuntherng, Erik Mannaert	17
2	The effect of food on the pharmacokinetics of oral ibrutinib in healthy participants and patients with chronic lymphocytic leukemia 2015 ·Cancer Chemotherapy and Pharmacology ·Jan de Jong, Juthamas Sukbuntherng, Donna Skee, Joe Murphy, Susan O’Brien, John C. Byrd, Danelle F. James, Peter Hellemans, David Loury, (unknown), Vijay S. Chauhan, Erik Mannaert	60
3	Population Pharmacokinetics of Rabeprazole and Dosing Recommendations for the Treatment of Gastroesophageal Reflux Disease in Children Aged 1–11 Years 2014 ·Clinical Pharmacokinetics ·Sarah McLeay, Bruce Green, William R. Treem, (unknown), Erik Mannaert, Holly Kimko	3
4	D2-receptor occupancy measurement of JNJ-37822681, a novel fast off-rate D2-receptor antagonist, in healthy subjects using positron emission tomography: single dose versus steady state and dose selection 2012 ·Psychopharmacology ·Mark E. Schmidt, Peter de Boer, Randolph D. Andrews, (unknown), Stefaan Rossenu, (unknown), Erik Mannaert	6
5	Population Pharmacokinetics of Oral Risperidone in Children, Adolescents and Adults with Psychiatric Disorders 2010 ·Clinical Pharmacokinetics ·(unknown), An Vermeulen, Eliane Fuseau, (unknown), Erik Mannaert	31
6	Dose-dependent effects of the CRF1 receptor antagonist R317573 on regional brain activity in healthy male subjects 2009 ·Psychopharmacology ·Mark E. Schmidt, Randolph D. Andrews, Peter van der Ark, Terry Brown, Erik Mannaert, Thomas Steckler, Jan de Hoon, Koen Van Laere	25
7	Maintenance therapy with once-monthly administration of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder: a pilot study of an extended dosing interval 2007 ·Annals of General Psychiatry ·Georges M. Gharabawi, (unknown), Robert Lasser, Ramy Mahmoud, Young Zhu, Erik Mannaert, (unknown), Cynthia A. Bossie, Mary J. Kujawa, George M. Simpson	26
8	Plasma Pharmacokinetic Characteristics of Risperidone and Their Relationship to Saliva Concentrations in Children with Psychiatric or Neurodevelopmental Disorders 2007 ·Clinical Therapeutics ·Michael G. Aman, Alexander A. Vinks, Bart Remmerie, Erik Mannaert, Yaser Ramadan, (unknown), Ronald L. Lindsay, (unknown)	35
9	Pharmacokinetics and dopamine d2 and serotonin 5-ht2a receptor occupancy of paliperidone in healthy subjects: two open-label, single-dose studies (PAL-115) 2007 ·Pharmacopsychiatry ·Per Karlsson, L. Hargarter, (unknown), Sigrid Nyberg, Erik Mannaert, Sandra Boom, Krishna Talluri, Stefaan Rossenu, Bo Eriksson, Mariëlle Eerdekens, Lars Farde	17
10	Pharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone (Risperdal Consta™) in patients with schizophrenia 2005 ·The International Journal of Neuropsychopharmacology ·О. Гефверт, Bo Eriksson, Per Persson, Lars Helldin, (unknown), Erik Mannaert, Bart Remmerie, Mariëlle Eerdekens, Svante Nyberg	88
11	Pharmacokinetic profile of long-acting injectable risperidone at steady-state : comparison with oral administration 2005 ·L Encéphale ·Erik Mannaert, An Vermeulen, Bart Remmerie, Philippe Bouhours, J. C. Levron	26
12	Plasma antipsychotic concentration and receptor occupancy, with special focus on risperidone long-acting injectable 2005 ·European Neuropsychopharmacology ·Rossella Medori, Erik Mannaert, Gerhard Gründer	29
13	Pharmacokinetic Profile and Clinical Efficacy of Long-Acting Risperidone 2005 ·Drugs in R&D ·Larry Ereshefsky, Erik Mannaert	31
14	Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia 2004 ·Schizophrenia Research ·Mariëlle Eerdekens, Ilse Van Hove, Bart Remmerie, Erik Mannaert	133
15	In vitro effects of risperidone and 9-hydroxy-risperidone on human platelet function, plasma coagulation, and fibrinolysis 2004 ·Clinical Therapeutics ·Fred De Clerck, Yves Somers, Erik Mannaert, Andrew Greenspan, Mariëlle Eerdekens	31
16	Pharmacokinetic comparison of fast-disintegrating and conventional tablet formulations of risperidone in healthy volunteers 2003 ·Clinical Therapeutics ·E.A. van Schaick, Philippe Lechat, Bart Remmerie, Grant N. Ko, Kenneth C. Lasseter, Erik Mannaert	37
17	Detection of 2-Amino-5-Chloropyridine in Urine as a Parameter of Zopiclone (Imovane®) Intake using HPLC with Diode Array Detection 1997 ·Journal of Analytical Toxicology ·Erik Mannaert, Jan Tytgat, Paul Daenens	20
18	Development of a fluorescence polarization immunoassay for the routine detection of N-desmethylzopiclone in urine samples 1996 ·The Analyst ·Erik Mannaert, Paul Daenens	9
19	Semi-preparative chiral resolution of zopiclone and N-desmethylzopiclone 1996 ·Journal of Pharmaceutical and Biomedical Analysis ·Erik Mannaert, Paul Daenens	8
20	Development of a radioimmunoassay for the determination of N-desmethylzopiclone in urine 1994 ·The Analyst ·Erik Mannaert, Paul Daenens	17

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact